These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38153186)

  • 1. The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias.
    Tokgozoglu L; Orringer C; Catapano AL
    Eur Heart J; 2024 Feb; 45(7):504-506. PubMed ID: 38153186
    [No Abstract]   [Full Text] [Related]  

  • 2. The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias.
    Tokgozoglu L; Orringer C; Catapano A
    Eur Heart J; 2023 Jan; 44(4):256-258. PubMed ID: 36587944
    [No Abstract]   [Full Text] [Related]  

  • 3. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and Treatment of Dyslipidaemias in Athletes.
    Christou GA; Kouidi EJ; Deligiannis AP; Kiortsis DN
    Curr Vasc Pharmacol; 2017; 15(3):238-247. PubMed ID: 28137212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
    Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 8. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of dyslipidemia: we don't know all we think we know.
    LeLorier J
    Can J Cardiol; 2006 Jul; 22(9):737-8. PubMed ID: 16913059
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrates consistently lower risk of cardiovascular events across high-risk groups.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):174. PubMed ID: 20532463
    [No Abstract]   [Full Text] [Related]  

  • 11. [To improve cardiovascular health: we are forced for not loosing impulse].
    Millán Núñez-Cortés J; Mantilla Morató T; Lobos Bejarano JM; Pedro-Botet Montoya J
    Clin Investig Arterioscler; 2016; 28(1):43-6. PubMed ID: 26589871
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007.
    Ferrières J; Bongard V; Dallongeville J; Arveiler D; Cottel D; Haas B; Wagner A; Amouyel P; Ruidavets JB
    Arch Cardiovasc Dis; 2009 Apr; 102(4):293-301. PubMed ID: 19427606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of dyslipidaemias.
    Paramsothy P; Knopp R
    Heart; 2006 Oct; 92(10):1529-34. PubMed ID: 16973811
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of dyslipidaemias -  present and future. Guidelines of the Angiology Section of the Slovak Medical Chamber (2013)].
    Gavornik P; Dukát A; Gašpar L;
    Vnitr Lek; 2013 Oct; 59(10):932-8. PubMed ID: 24164369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 16. Best Practice & Research Clinical Endocrinology & Metabolism. Pharmacological treatment of dyslipidaemias. Preface.
    Rubenfire M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):279. PubMed ID: 24840258
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing cardiovascular risk and managing dyslipidemia in women.
    Appel SJ; Floyd NA; Jones EJ
    Nurs Womens Health; 2007 Dec; 11(6):586-99. PubMed ID: 18088296
    [No Abstract]   [Full Text] [Related]  

  • 18. Atherogenic dyslipidemia.
    Hayden MR
    J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement in the Management of Dyslipidemia in a Clinical Practice Population at Very High Cardiovascular Risk. The COLIPAR Project.
    Cosín-Sales J; Gisbert-Criado R; Maceira AM; Buendía F; Gómez Ribelles R; Ruvira J
    Rev Esp Cardiol (Engl Ed); 2018 Nov; 71(11):979-980. PubMed ID: 29037611
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice.
    Varughese GI; Scarpello JH
    Int J Clin Pract; 2006 Jul; 60(7):884-8. PubMed ID: 16846405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.